From a translational standpoint, the identification of tramadol as a modulator of the HIF-1α/ATF4 axis provides new insights into therapeutic strategies targeting stress-adaptive pathways in resistant breast cancer subtypes. The gene discussed is ATF4; the disease is breast carcinoma.